{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"910","value":"2270"},{"groupId":"OG001","spread":"1320","value":"3070"}]}],"title":"EDO-S101"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.45","value":"2.85"},{"groupId":"OG001","spread":"0.633","value":"2.23"}]}],"title":"M2-EDO-S101"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.58","value":"52.4"},{"groupId":"OG001","spread":"11.5","value":"60.4"}]}],"title":"M8-EDO-S101"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Cmax was defined as maximum observed plasma concentration. Tinostamustine (EDO-S101) and its metabolites included M2-EDO-S101 and M8-EDO-S101.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received single dose of tinostamustine 180 mg/m\\^2 IV injection followed by autologous stem cell transplantation (ASCT) on Day 1.","id":"OG000","title":"Tinostamustine 180 mg/m^2"},{"description":"Participants received single dose of tinostamustine 220 mg/m\\^2 IV injection followed by ASCT on Day 1.","id":"OG001","title":"Tinostamustine 220 mg/m^2"}],"paramType":"MEAN","populationDescription":"PK population included all participants in the safety population with at least one quantifiable pre-dose and one quantifiable post-dose PK plasma concentration. The study was early terminated on 17 April 2019, due to safety signals during Phase 1, participants were not enrolled in Phase 2.","reportingStatus":"POSTED","timeFrame":"Pre-infusion, 0.50, 0.75, 1, 3, 6, 24, 48 hours post-infusion","title":"Phase 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Tinostamustine and Its Metabolites","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}